Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.52% | 93.20% | -15,916.67% | 74.36% | 22.04% |
| Total Depreciation and Amortization | -14.91% | -18.43% | -23.30% | -27.05% | -10.27% |
| Total Amortization of Deferred Charges | 136.67% | 240.46% | 536.73% | 301.12% | 200.00% |
| Total Other Non-Cash Items | -11.61% | -99.64% | 283.48% | -77.49% | -76.40% |
| Change in Net Operating Assets | -64.50% | -77.39% | -54.81% | -45.08% | 276.74% |
| Cash from Operations | -88.20% | -122.17% | -105.57% | 228.74% | 425.65% |
| Capital Expenditure | -673.03% | 16.96% | -49.17% | 76.48% | 89.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.33% | -14.12% | 9.09% | 38.96% | -111.29% |
| Cash from Investing | -293.13% | 9.22% | -28.54% | 68.68% | -150.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -3,335.00% | 0.00% | 67.21% |
| Issuance of Common Stock | -100.00% | -- | -99.38% | -100.00% | -75.66% |
| Repurchase of Common Stock | -- | 60.00% | 89.00% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.34% | 0.00% | -- | -57.76% | -- |
| Cash from Financing | 96.98% | 99.25% | 280.47% | -160.74% | -810.73% |
| Foreign Exchange rate Adjustments | -94.62% | -166.37% | 111.85% | -122.43% | 15,700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.38% | -205.42% | 489.80% | -219.96% | 1,015.94% |